Research programme: antibodies - OstriGen
Latest Information Update: 27 Sep 2023
Price :
$50 *
At a glance
- Originator OstriGen
- Developer Beth Israel Deaconess Medical Center; Kyoto Prefectural University of Medicine; Massachusetts General Hospital; OstriGen; United States Army Medical Research Institute of Infectious Diseases
- Class Antibacterials; Antibodies; Antidiarrhoeals; Antivirals
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cholera; Clostridium difficile infections; Diarrhoea; Ebola virus infections; Escherichia coli infections; Norovirus infections; Salmonella infections; Shigella infections; Zika virus infection
Most Recent Events
- 27 Sep 2023 Research programme: antibodies is still in preclinical phase for Clostridium-difficile-infections (Prevention) in Japan (PO) (OstriGen Website - 2023)
- 27 Sep 2023 Research programme: antibodies is still in preclinical phase for Clostridium-difficile-infections in Japan (PO) (OstriGen Website - 2023)
- 27 Sep 2023 Research programme: antibodies is still in preclinical phase for Cholera (Prevention) in USA (PO) (OstriGen Website - 2023)